Andelyn Biosciences, Inc., a cell and gene therapy CDMO, has partnered with Purespring Therapeutics, a biotech innovator company, to accelerate the manufacture of their gene therapies for the treatment of chronic renal diseases. Purespring will leverage Andelyn’s experience in adeno-associated virus (AAV) production and adapt Andelyn’s suspension platform to manufacture its preclinical and clinical gene therapy products under GMP.  Matt Niloff, chief commercial officer of Andelyn, said, “A...